Mirna Therapeutics Company Profile (NASDAQ:MIRN)

Analyst Ratings

Consensus Ratings for Mirna Therapeutics (NASDAQ:MIRN) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.00 (160.66% upside)

Analysts' Ratings History for Mirna Therapeutics (NASDAQ:MIRN)
Show:
DateFirmActionRatingPrice TargetActions
5/13/2016Cantor FitzgeraldReiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Leerink SwannLower Price TargetOutperform$14.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Citigroup Inc.Lower Price Target$9.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015Oppenheimer Holdings Inc.Reiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Mirna Therapeutics (NASDAQ:MIRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
11/13/2015        
11/13/2015Q315($82.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Mirna Therapeutics (NASDAQ:MIRN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.43)($0.43)($0.43)
Q2 20162($0.50)($0.43)($0.47)
Q3 20162($0.56)($0.46)($0.51)
Q4 20162($0.56)($0.46)($0.51)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Mirna Therapeutics (NASDAQ:MIRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Mirna Therapeutics (NASDAQ:MIRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
10/6/2015Michael PowellDirectorBuy857,142$7.00$5,999,994.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Mirna Therapeutics (NASDAQ:MIRN)
DateHeadline
07/06/16 04:19 PMMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
07/05/16 06:21 AMMirna Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced ...
07/05/16 06:00 AMMirna Therapeutics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference - [Business Wire] - Mirna Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced that President and Chief Executive Officer Paul Lammers, M.D., M.Sc., will present a corporate overview at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 10:15 a.m.
07/01/16 05:11 PMMIRNA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders (form 8-K)
06/30/16 04:30 PMMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters to a V -
06/30/16 06:21 AMMirna Therapeutics Appoints Perry Nisen, M.D., Ph.D., to Its Board of Directors - [at noodls] - AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced ...
06/08/16 05:07 PMMirna Therapeutics, Inc. :MIRN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/06/16 11:28 AMMirna Therapeutics Announces Clinical Data on its Lead microRNA Therapeutic Presented at ASCO - [at noodls] - Oral presentation highlights safety profile of MRX34, microRNA target engagement, and multiple clinical responses in cancer patients CHICAGO--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq: MIRN), ...
06/03/16 07:58 AMAustin-area Public Companies list - Even so, It may still be awhile until revenues and employees catch up to last year's levels, as three of our public companies reported zero revenue during 2015: Mirna Therapeutics, Pain Therapeutics and XBiotech. All three firms are biopharmaceutical ...
06/02/16 05:32 PMMarina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael French - About Marina Biotech, Inc. Marina Biotech is an oligonucleotide therapeutics ... through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. In addition to these ...
06/02/16 08:04 AMmiRagen Therapeutics Receives ALS Association Grant to Advance the Development of MRG-107 - About miRagen Therapeutics, Inc. miRagen Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative microRNA (miRNA)-targeting therapies in disease areas of high unmet medical need. The Company ...
05/30/16 06:20 PMMirna Therapeutics, Inc. (MIRN) Broker Price Targets For The Coming Week - Share Trading News - Mirna Therapeutics, Inc. (MIRN) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Mirna Therapeutics, Inc. (MIRN). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy ...
05/12/16 05:52 PMMirna Therapeutics reports 1Q loss -
05/12/16 04:27 PMMirna Therapeutics Reports First Quarter 2016 Financial Results and Program Updates - [at noodls] - AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today reported financial ...
05/03/16 10:35 AMMarina Biotech Terminates Negotiations for Sale of Its Nucleic Acid Therapeutic Assets - About Marina Biotech, Inc. Marina Biotech is an oligonucleotide therapeutics ... through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries ...
04/27/16 11:31 AMMIRNA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer. The foregoing description of the material terms of the Agreement and general release of claims is ...
04/25/16 06:25 AMMirna Therapeutics Appoints Vincent J. O'Neill, M.D., as Chief Medical Officer - [at noodls] - AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced ...
04/25/16 06:00 AMMirna Therapeutics Appoints Vincent J. O’Neill, M.D., as Chief Medical Officer - [Business Wire] - Mirna Therapeutics, Inc. , a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of Vincent J.
04/22/16 11:25 AMMARINA BIOTECH CMN (OTCMKTS:MRNA) Shorts Decreased by 45.93% After Short Covering - It has a 1.7 P/E ratio. The Company’s partners, ProNAi Therapeutics, Inc. (ProNAi) and Mirna Therapeutics, Inc. (Mirna) are focused on oncology and have clinical programs in recurrent or refractory non-Hodgkin’s lymphoma and unresectable primary liver ...
04/20/16 07:52 AM8:52 am Mirna Therapeutics announces results in 2 data presentations at the annual meeting of the American Association for Cancer Research -
04/20/16 07:51 AMMirna Therapeutics Announces Data Presentations at the Annual Meeting of the American Association for Cancer Research - [at noodls] - Results reported in two poster presentations suggest MRX34 combination regimens may enhance effectiveness of standard cancer therapies AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), ...
04/13/16 10:41 AMAnalyst Highlights Regulus Therapeutics' 'Disruptive 2016 Catalysts' - Chardan Capital’s Madhu Kumar expects Regulus Therapeutics Inc (NASDAQ: RGLS)'s assets to witness several ... has demonstrated a leadership role in the development of microRNA (miRNA) therapeutics,” Kumar mentioned. Among the catalysts expected ...
04/02/16 12:04 PMMIRNA THERAPEUTICS, INC. Financials -
03/31/16 09:48 AMMarina Biotech Provides 2015 Year-End Financials and Update - About Marina Biotech, Inc. Marina Biotech is an oligonucleotide therapeutics ... through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries and ...
03/30/16 09:52 AMAustin biotech firm's IPO for cancer drugs may not be as big as originally thought - Two other Austin drug developers, XBiotech USA Inc. and Mirna Therapeutics Inc., both went public in 2015 amid a rush by biotech firms to come to market. As I examined in a feature ABJ article last December, the market for health care IPOs hit a hefty ...
03/30/16 09:52 AMMIRNA THERAPEUTICS : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Item 2.02 Results of Operations and Financial Condition. On March 29, 2016, Mirna Therapeutics, Inc. ("Mirna") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2015. The press release is attached ...
03/30/16 09:52 AMMirna Therapeutics's (MIRN) CEO Paul Lammers on Q4 2015 Results - Earnings Call Transcript - Greetings and welcome to the Mirna Therapeutics Inc. Fourth Quarter and Full Year 2015 Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a ...
03/30/16 05:21 AMMIRNA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report -
03/29/16 03:24 PMMirna Therapeutics Provides Operational Update and Reports Financial Results for Fourth Quarter and Full Year Ended December 31, 2015 - [at noodls] - Management to host conference call and webcast today at 5 p.m. Eastern AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical stage biopharmaceutical company developing a broad ...
03/22/16 09:50 AMMIRNA THERAPEUTICS : to Host Conference Call and Webcast of Fourth Quarter and.. - Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced that the Company will host a conference call and live webcast on Tuesday, March 29 ...
03/22/16 07:05 AMMirna Therapeutics to Host Conference Call and Webcast of Fourth Quarter and Full Year 2015 Financial Results on March 29, 2016 - [at noodls] - AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced ...
03/16/16 07:30 AMMarina Biotech Announces a License Agreement to Deliver a Genome Editing Technology - [Marketwired] - Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that they have entered into a license agreement covering the company's ...
03/15/16 09:39 AMMicrolin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech - About Microlin Bio, Inc. Microlin Bio, Inc. is a development stage biotechnology ... through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries ...
02/29/16 09:04 AMRosetta Genomics Appoints Ana C. Ward As Executive Vice President, Legal And Corporate Development - Previously she was General Counsel and Senior Vice President for Asuragen, Inc. and its spin-off, Mirna Therapeutics, where she managed a diverse portfolio of legal matters, including FDA, GMP, GLP, and CLIA compliance and regulations, intellectual ...
02/18/16 07:30 AMMarina Biotech Announces Evaluation and Option Agreement to Deliver a Genome Editing Technology - [Marketwired] - Marina Biotech, Inc. , a leading nucleic acid-based drug discovery and development company focused on rare diseases announced today that they have entered into an evaluation and option agreement regarding ...
02/17/16 08:44 AMMarina Biotech to Explore Strategic Alternatives - About Marina Biotech, Inc. Marina Biotech is an oligonucleotide therapeutics ... through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries ...
02/03/16 06:00 AMMirna Therapeutics to Present at the BIO CEO & Investor and LEERINK Global Healthcare Conferences in February - [Business Wire] - Mirna Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced its participation in two healthcare investor conferences during the month of February.
02/01/16 03:17 PMMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi -
02/01/16 06:30 AMMirna Therapeutics Appoints Peter Greenleaf to Its Board of Directors - [at noodls] - --(BUSINESS WIRE)-- (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the appointment of to the Company's Board ...
01/07/16 03:11 PMMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -
01/06/16 05:27 PMRosetta Genomics Grants Sublicenses to Mirna Therapeutics for microRNA-related Patents for the Development of Oncology Therapeutics - [at noodls] - Microsoft Word - 010616 ROSG Mirna Tx Sublicense FINAL.docx News Release PHILADELPHIA, REHOVOT, Israel (January 6, 2016) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based ...
12/02/15 06:16 AMMirna Therapeutics to Present at the Oppenheimer 26th Annual Healthcare Conference - [at noodls] - AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced ...
12/01/15 08:00 AMTechnical Data Reveals Conditions of Growth - Research on Entegra Financial, Fate Therapeutics, Provident Bancorp, and Mirna Therapeutics - [Accesswire] - NEW YORK, NY / ACCESSWIRE / December 1, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Entegra Financial ...
11/23/15 09:29 AMMirna Therapeutics Announces the Publication of New Data Supporting Potential Immune-Related Mechanism for Anti-Cancer Activity of MRX34 - [at noodls] - AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapies, today announced that ...
11/13/15 06:26 AMMirna Therapeutics Reports Third Quarter Financial Results and Recent Highlights - [at noodls] - Demonstrated confirmed partial responses in liver cancer and melanoma in Phase 1 clinical trial of lead product candidate MRX34 Completed IPO and concurrent private placement in October with aggregate ...
11/13/15 06:02 AMMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
11/13/15 05:17 AMMIRNA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report -
11/09/15 06:16 AMMirna Therapeutics Announces Presentation of Interim Data from Ongoing Phase I Clinical Trial of MRX34, First-in-Class microRNA-34 mimic, in Patients with Advanced Solid Tumors - [at noodls] - Data presented at AACR-NCI-EORTC International Conference AUSTIN, Texas--(BUSINESS WIRE)-- Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline ...

Social

About Mirna Therapeutics

Mirna Therapeutics logoMirna Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of microRNA (ribonucleic acid)-based oncology therapeutics. It is developing a cancer therapy, microRNA Replacement Therapy, focused on replacing naturally occurring microRNAs that are under expressed in cancer cells with microRNA mimics. Its pipeline of products includes MRX34, miR-101, miR-215, let-7 and miR-16. The Company's lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is in Phase I clinical trial in patients with primary liver cancer, advanced solid tumors and hematological malignancies. Its miR-34 is considered a key regulator of multiple oncogenes across key oncogenic pathways. The Company focuses on developing MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MIRN
  • CUSIP:
Key Metrics:
  • Previous Close: $4.22
  • 50 Day Moving Average: $4.39
  • 200 Day Moving Average: $4.52
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $87.90M
  • Current Year EPS Consensus Estimate: $-1.57 EPS
  • Next Year EPS Consensus Estimate: $-1.78 EPS
Additional Links:
Mirna Therapeutics (NASDAQ:MIRN) Chart for Monday, July, 25, 2016